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Purpose: The tyrosine kinase inhibitors (TKIs) gefitinib and erlo-
tinib are effective in non-small cell lung cancers (NSCLCs) with
epidermal growth factor receptor (EGFR) gene mutations. The
usual clinical dose of gefitinib (250 mg/d) is only one third of its
maximum tolerated dose, whereas the dose of erlotinib (150 mg/d)
is at its maximum tolerated dose. In NSCLC cell lines, both TKIs
have similar micromolar inhibitory concentrations. We explored
whether erlotinib at 25 mg/d (trough serum concentration similar to
gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC.
Methods: To study the inhibitory concentrations of gefitinib and
erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255,
PC-9, and H1975) to increasing concentrations of these TKIs.
Further on, we performed a retrospective evaluation of seven pa-
tients with advanced EGFR-mutated (exon 19 deletions and L858R)
NSCLC that were given erlotinib at 25 mg/d as their first EGFR
TKI.
Results: Gefitinib and erlotinib generated similar inhibitory curves
across our panel of EGFR-mutated NSCLC cell lines with overlap-
ping mean 50% inhibitory concentration 95% confidence intervals
for HCC827, PC-9, and H1975. Both drugs also displayed a high
degree of correlation in mean 50% inhibitory concentration (Pear-
son’s r  0.99, p  0.0417). Of the seven patients, five patients
(71.5%) had partial responses to erlotinib 25 mg/d. Median progres-
sion-free survival was 17 months (95% confidence interval, 6–35
months). Toxicities were minimal, with only two (28.5%) patients
having a rash and none experiencing (0%) diarrhea.
Conclusions: In NSCLC cell lines, gefitinib and erlotinib have
similar inhibitory profiles. In patients with NSCLC and EGFR-
activating mutations, a dose of erlotinib 25 mg/d (equivalent to
gefitinib 250 mg/d) leads to impressive response rates and progres-
sion-free survival similar to the growing experience with the ap-
proved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d).
Identifying prospectively the lowest and clinically active dose
ranges of erlotinib and gefitinib will help further to personalize care
for patients with tumors harboring EGFR mutations.
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Somatic mutations in the tyrosine kinase domain of theepidermal growth factor receptor (EGFR) gene were
identified in patients with non-small cell lung cancer
(NSCLC) in 2004.1–3 These mutations are more prevalent in
women, never or light smokers, patients with East Asian
ancestry, and patients whose tumors demonstrate adenocar-
cinoma histology.4 Most clinically relevant EGFR mutations
consist of a single point mutation (L858R) in exon 21 and
inframe deletions around the conserved LREA (leucine, ar-
ginine, glutamic acid, alanine) motif of exon 19 (residues
747–750).5 EGFR mutations are oncogenic, alter the tyrosine
kinase pocket of EGFR to a degree that enhances the sensi-
tivity to ATP-competitive EGFR inhibitors, and make lung
cancers with EGFR mutations dependent on EGFR signaling
for their survival and proliferation.6
Two EGFR tyrosine kinase inhibitors (TKIs) have
reached regulatory approval for NSCLC: gefitinib and erlo-
tinib.7–9 When given as first, second, or subsequent lines of
therapies for patients with EGFR mutations, these agents lead
to significant clinical and radiographic responses in most
patients.10 The reported response rates (RRs) exceed 70%,
with median progression-free survival (PFS) intervals of
approximately 6 to 12 months and overall survival times
beyond 20 to 24 months.11,12 Gefitinib improves RR and PFS
when compared with standard platinum-doublet chemother-
apy in therapy naive patients with metastatic EGFR-mutated
NSCLC.13 Erlotinib is equally efficacious in EGFR-mutated
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tumors when given as a first line therapy but has not been
compared head-to-head with chemotherapy in the published
reports.14
NSCLCs that harbor activating EGFR mutations are
sensitive to gefitinib or erlotinib in equivalent submicromolar
concentrations.6 Despite the similar in vitro spectrum of
action in NSCLC cells, the clinical development and thera-
peutic doses used in the clinic for these two TKIs, which were
initially developed to target wild-type EGFR, differs. The
dose of gefitinib (250 mg/d) that entered late stage clinical
trials for NSCLC is only one third of its maximum tolerated
dose (MTD), whereas the dose used for erlotinib (150 mg/d)
is its MTD.15,16 Data from phase I dose-escalation trials show
that the expected mean trough steady state serum concentra-
tion of gefitinib at 250 mg/d is approximately 0.5 M,17
whereas erlotinib at 150 mg/d has mean trough steady state
concentrations that exceed 2.5 M.18 This knowledge led us
to hypothesize that erlotinib at 25 mg/d (its lowest available
tablet size with presumed trough serum concentration around
0.5 M) would be active in EGFR-mutated NSCLC.
Here, we confirm that both gefitinib and erlotinib have
similar in vitro inhibitory concentrations in NSCLC cells with
EGFRmutations and demonstrate that erlotinib 25 mg/d leads
to a high RR and PFS in patients with NSCLC harboring
EGFR-activating mutations.
MATERIALS AND METHODS
Reagents
Gefitinib and erlotinib were purchased from a commer-
cial supplier. Stock solutions for gefitinib and erlotinib were
prepared as described previously.19
Cell Culture
The human lung cancer–derived cells lines NCI-H1975
(H1975), NCI-H3255 (H3255), PC-9, and HCC827 were
maintained in Roswell Park Memorial Institute culture me-
dium supplemented with 10% fetal bovine serum.
Cell Proliferation Assay
Growth inhibition was assessed by CellTiter 96 AQue-
ous One solution proliferation kit (Promega, Madison, WI) as
previously described.20,21 Briefly, cells were transferred to
wells at 1500 to 5000 cells/well (for H1975, 1500; for
HCC827, 2,500; for PC-9, 3,500, and for H3255, 5000) in
96-well flat-bottom plates with various concentrations of
inhibitors and incubated for 72 hours before photometric
analysis. Experiments were repeated for three times.
Patient Selection
Patients were identified retrospectively from the clini-
cal databases of two academic medical centers: (1) Beth
Israel Deaconess Medical Center and (2) Memorial Sloan-
Kettering Cancer Center. Both centers have institutional-
approved protocols for chart review and genomic analysis of
stored tumor tissues. Inclusion criteria to use the patient’s
data included a diagnosis of stage IV metastatic NSCLC with
a proven EGFR mutation and exposure to erlotinib at a dose
of 25 mg daily. Data were collected from the patients’
medical records for clinical, demographic, and pathologic
characteristics and toxicity. Radiographic data was reviewed
by each center. Treatment decisions were made by each
treating physician.
EGFR Genotype in the Identified Patients
DNA isolation from paraffin-embedded tissue and
EGFR genotype followed protocols described previously.15
In all cases, either exons 18 to 21 of the EGFR gene were
sequenced or sensitive polymerase chain reaction amplifica-
tion techniques identified L858R and deletions in exon 19.
Treatment Schedules, Response, Progression-
Free Survival Assessment, and Statistical
Analysis in the Identified Patients
All retrospectively identified patients had the same
initial treatment schedule for erlotinib. This medication was
given orally at a dose of 25 mg/d, and erlotinib was used until
tumor progression, unacceptable toxicity, or at the physi-
cian’s discretion. Because the patients identified had been
treated as a part of routine clinical care, the investigators had
no control of the dosing schedules and follow-up proposed by
each treating physician. Objective tumor response was deter-
mined retrospectively by RECIST version 1.0.22 PFS was
calculated from the date of starting erlotinib until the date of
radiographic tumor progression. All patients had adverse
reactions determined, by chart extraction, while receiving
erlotinib according to the Common Terminology Criteria for
Adverse Events, version 3.0. The data cutoff for analysis of
PFS and other endpoints was February 1, 2010.
Statistical Analysis
The inhibitory proliferation curves and the 50% inhib-
itory concentration (IC50) in the aforementioned proliferation
assays were generated and calculated, respectively, using the
GraphPad Prism version 5 software (GraphPad Software Inc,
La Jolla, CA). Pearson’s correlation coefficient (r) was used
as a measure of association between IC50s for gefitinib and
erlotinib. A log transformation was applied to the dose data,
and the exact two-sided p value was calculated using StatXact
(Cytel Software Corporation, Cambridge, MA). PFS esti-
mates were made using the Kaplan-Meier method,23 and the
95% confidence interval (CI) for the median was based on the
sign test. Analysis was conducted with SAS version 9.1 (SAS
Institute, Cary, NC).
RESULTS
In Vitro Inhibitory Concentration of Gefitinib
and Erlotinib in NSCLC Cells with EGFR-
Activating Mutations
We selected a set of NSCLC cell lines to identify the
sensitivity of EGFR-mutated cells to the effects of increasing
concentrations of gefitinib and erlotinib. HCC827 and PC-9
have an identical exon 19 deletion (delE746_A750).20 H3255
carries the L858R EGFR exon 21 point mutation.2 H1975
carries the L858R mutation in association with the T790M
EGFR TKI-resistant mutation.24
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After exposure to increasing concentrations of gefitinib
or erlotinib, HCC827, PC-9, and H3255 had their prolifera-
tion inhibited by these EGFR TKIs in sub 0.5 M concen-
trations (Figure 1). H1975 cells were not significantly inhib-
ited up to 5 M of exposure (Figure 1).
As indicated in Figure 1, both gefitinib and erlotinib led
to similar inhibitory curves across our sample of EGFR-
mutated cells. At concentrations between 0.001 and 1 M,
the curves overlapped for HCC827, PC-9, and H1975.
The calculated mean IC50 for gefitinib was 0.002686
M (95% CI, 0.001649–0.004376) for HCC827, 0.02632
M (95% CI, 0.01748–0.03963) for PC-9, 0.03843 M
(95% CI, 0.03149–0.04690) for H3255, and 11.580 M
(95% CI, 9.827–13.660) for H1975. The mean IC50 for
erlotinib was 0.002142 M (95% CI, 0.001307–0.003510)
for HCC827, 0.03136 M (95% CI, 0.02082–0.04724) for
PC-9, 0.08898 M (95% CI, 0.07294–0.1085) for H3255,
and 9.183 M (95% CI, 7.640–11.040) for H1975.
The mean IC50 values for both gefitinib and erlotinib in
three of four EGFR-mutated cell lines had overlapping 95%
CIs (HCC827, PC-9, and H1975). Gefitinib and erlotinib also
had a high degree of correlation in mean IC50 (Pearson’s r 
0.99, p  0.0417). These results indicate that both EGFR
inhibitors have similar inhibitory patterns in EGFR-mutated
cells and that they are strongly correlated.
Patient Characteristics
Records of EGFR genotyped patients from our centers
during the periods of 2004 to 2010 were reviewed. We
retrospectively identified seven EGFR-mutated patients that
had received erlotinib at a dose of 25 mg daily as their first
EGFR TKI.
Clinical, demographic, pathologic, and molecular char-
acteristics of this cohort are displayed in Table 1. Medical
record extraction and direct confirmation with the treating
physician identified that in all cases, the treating physician
offered the dose of 25 mg daily of erlotinib because of its
supposed equivalence to gefitinib 250 mg daily and that
patients were informed that the 25 mg dose was not the
standard dose of erlotinib for NSCLC. In one of the cases
(patient 4, Table 2), notes from the treating physician also
reported a previous history of treated hepatitis B as a reason
to offer erlotinib at 25 mg daily.
Response and PFS to Erlotinib 25 mg/d
Five of the seven patients (71.5%) had partial radio-
graphic responses as defined by RECIST to erlotinib (Table
2), a number that is compatible with retrospective and pro-
spective data for EGFR-mutated patients treated with ge-
fitinib 250 mg/d or erlotinib 150 mg/d.25 Two patients
(28.5%) had stable disease, and none of the patients had de
FIGURE 1. Proliferation assays of non-small cell lung cancer cells exposed to gefitinib (—) and erlotinib (---) for 72 hours. A,
HCC827 (n  3). B, PC-9 (n  3). C, H3255 (n  3). D, H1975 (n  3).
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novo resistance to erlotinib with progressive disease as best
response.
The median PFS calculated by the Kaplan-Meier
method was 17 months (95% CI, 6–35 months) as shown in
Figure 2. Individual PFS and the patients’ dose schedules
while using erlotinib 25 mg/d are detailed in Table 2.
Adverse Reactions to Erlotinib 25 mg/d
There were no grade 3 or 4 adverse events recorded
during the treatment period, and no patients discontinued
erlotinib because of unacceptable toxicity. Only two of seven
(29%) patients developed a grade 1 rash while on erlotinib,
and none (0%) developed diarrhea (Table 2). The only other
toxicity recorded was related to liver test abnormalities in one
of the patients (Table 2) that improved with use of erlotinib
at 25 mg every other day. Clinical or radiographic signs of
interstitial pulmonary fibrosis or pneumonia were not seen in
these patients.
DISCUSSION
Gefitinib and erlotinib are orally available anilino-
quinazoline small molecule ATP-mimetic TKIs most specific
against EGFR. The molecular weight of gefitinib is 446.90
g/mol, and gefitinib’s clinical dose for NSCLC of 250 mg/d
is far less than its MTD of 700 to 1000 mg/d.16,17,26,27 Based
on a phase I dose-escalation trial, the mean steady state
trough serum concentration of gefitinib following 225 mg/d
averaged 0.16 g/ml or a calculated 0.358 M.17 The mean
trough concentration increased to 0.24 g/ml or 0.537 M at
300 mg/d and to 1.1 g/ml or 2.461 M at 1000 mg/d of
gefitinib.17 The molecular weight of erlotinib is 429.90 g/mol,
and its clinical dose of 150 mg/d is its MTD.7,18 In a phase I
dose-escalation trial, erlotinib’s steady state trough concen-
trations at 150 mg/d ranged from 0.33 to 2.64 g/ml,18 with
a median of 1.26 g/mL or the equivalent to 2.930 M. In
the same trial, a dose of 25 mg/d led to a median trough
less than 0.22 g/ml or the equivalent to less than 0.511
M.18 Therefore, erlotinib is given at a higher biologically
active dose than gefitinib in routine clinical practice.16 In
agreement with the pharmacokinetic data, in the larger
phase III randomized trials of these TKIs versus placebo
for NSCLC,7,9 the rates of rash and diarrhea (the two most
common and dose-dependent side effects of these drugs)
were higher (almost double) with erlotinib 150 mg/d7 than
gefitinib 250 mg/d.9
Despite their different clinical development paths for
unselected NSCLCs, both gefitinib and erlotinib have a sim-
ilar spectrum of activity in vitro against EGFR mutant pro-
teins or EGFR-mutated tumors.2,28,29 Gefitinib 250 mg/d has
proven highly effective in prospective and retrospective se-
ries of patients with EGFR-activating mutations consistently
yielding RRs that exceed 70% is chemotherapy-naive patients
and PFS times that can reach more than 9 months.12,13
Erlotinib 150 mg/d is equally effective in EGFR-mutated
NSCLC.5,14 However, both drugs have never been compared
head-to-head in a clinical trial of patients with EGFR muta-
tions, and until now, it was unknown whether a “lower” dose
of erlotinib could generate similar responses to gefitinib 250
mg/d. Based on the pharmacokinetic data of phase I trials for
both compounds and their similar in vitro inhibitory profile, a
dose of erlotinib 25 mg/d seemed to best represent a dose of
gefitinib 250 mg/d.17,18 At these doses, both drugs are ex-
pected to have average trough concentrations of approxi-
mately 0.5 M, a concentration that far exceeds the IC50 of
most EGFR-mutated cells lines treated with these EGFR
TKIs. Serum trough concentrations are only surrogate mark-
ers of doses of these EGFR TKIs. Gefitinib has a higher
distribution volume than erlotinib, and drug concentrations in
the tumor may be higher with gefitinib than erlotinib.16 We
and others16,30 were able to determine that gefitinib and
erlotinib inhibit EGFR-mutated cell lines with similar inhib-
itory curves and remarkable correlation in IC50 values. There-
fore, at similar molar concentrations, both EGFR inhibitors
are expected to have a comparable spectrum of activity. This
hypothesis drove our rationale to evaluate the clinical out-
comes obtained with erlotinib 25 mg/d in patients with
advanced NSCLC and EGFR mutations.
Our compiled retrospective clinical data of seven pa-
tients treated with erlotinib at its lowest available tablet size
of 25 mg/d reinforces our assumptions. The radiographic RR
was extraordinarily high at 71.5% in this small cohort of
patients. Despite the retrospective nature of the analysis, the
PFS values observed are similar to those reported previously
with gefitinib 250 mg/d12 based on a lower bound of 6 months
for the 95% CI for median PFS in our cohort. The lack of
significant adverse reactions in most of our treated patients is
also consistent with a lower trough concentration of erlotinib
when this drug is given at 25 mg instead of 150 mg. Rash and
diarrhea, hallmark and dose-dependent side effects of EGFR
inhibitors, were not frequent in our patients. Indeed, only two
patients (28.5%) had a minor rash to erlotinib 25 mg/d. None
TABLE 1. Clinical, Pathologic, Demographic, and Molecular
Characteristics of the Studied EGFR-Mutated Patients
Characteristic Patients, N (%)
Age (yr), median (range) 65 (55–86)
Sex
Female 5 (71.5)
Male 2 (28.5)
Smoking history
Never smoker 1 (14.2)
Former smoker 5 (71.5)
Current smoker 1 (14.2)
Histology
Adenocarcinoma 6 (85.7)
NSCLC-NOS 1 (14.2)
EGFR mutation
Exon 19 deletiona 5 (71.5)
L858R 2 (28.5)
Therapy before erlotinib
Platinum-based chemotherapy 2 (28.5)
No previous therapy 5 (71.5)
a Specific EGFR sequences of the exon 19 deletions are detailed in Table 2.
EGFR, epidermal growth factor receptor; NSCLC-NOS, non-small cell lung can-
cer-not otherwise specified.
Journal of Thoracic Oncology • Volume 5, Number 7, July 2010 Erlotinib at 25 mg for EGFR-Mutated Lung Cancers
Copyright © 2010 by the International Association for the Study of Lung Cancer 1051
of our patients experienced interstitial pulmonary fibrosis, a
known and serious side effect of EGFR TKIs.31 The only
other toxicity noted in one patient was liver function test
abnormalities, which are well-described idiosyncratic side
effects of EGFR TKIs.7,9
EGFR-mutated patients treated with gefitinib or erlo-
tinib invariably develop acquired resistance to TKI therapy.25
The EGFR-T790M mutation19,24 accounts for half of cases,
other secondary resistance mutations (L747S, D761Y,
T854A) have been reported infrequently,20,32,33 and hepato-
cyte growth factor receptor (MET) amplification34,35 or ex-
pression of hepatocyte growth factor36 are detected in more
than one fifth of patients with EGFR-mutated TKI-resistant
NSCLC. The pattern of resistance seems similar between
patients treated with gefitinib 250 mg/d or erlotinib 150
mg/d.25,37 Cells with EGFR-T790M and MET amplification
cannot be inhibited with the use of gefitinib or erlotinib by in
vitro doses equivalent to their MTDs.21,34,35 In patient 1
(Table 2) of this study, an increase of erlotinib to 150 mg/d
after progression on erlotinib 25 mg/d was attempted without
changing the progressive nature of the tumor’s radiographic
disease (data not shown). Dose escalations to 150 mg/d were
not made by treating physicians in the other six patients
analyzed. Therefore, it is difficult to speculate whether erlo-
tinib at 25 mg/d or at other dose ranges less than 150 mg/d38
will alter the course and type of acquired resistance that
treated patients will experience.
Our small retrospective study is hypothesis generating
and will need to be confirmed in larger prospective series of
NSCLC patients. Future prospective clinical trials of erlotinib
at 25 mg daily and randomized trials of 25 mg versus 150 mg
daily doses of erlotinib or of gefitinib 250 mg versus erlotinib
150 mg daily in advanced EGFR-mutated NSCLC may shed
light on the differential efficacy, time to acquisition of resis-
tance, safety, and quality of life attained by these different
dosing approaches of approved EGFR TKIs.
In summary, our data indicate that EGFR-mutated
NSCLC lines with activating sensitive mutations are inhibited
by similar concentrations of gefitinib and erlotinib in vitro (0.5
M) and that erlotinib 25 mg/d (a concentration expected to be
similar to gefitinib 250 mg/d) may be an alternative dosing
scheme for patients with EGFR mutations. Future identification
of the lowest and clinically active dose ranges of erlotinib and
gefitinib in patients with tumors harboring EGFRmutations will
help further to personalize their care.
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TABLE 2. Clinical, Pathologic, Demographic, Molecular Characteristics, Response to Therapy, and Progression-Free Survival
in the Studied Patients
Patient
Clinical, Pathologic, and Molecular Characteristics
Efficacy
Toxicity (Grade-CTCAE)
Age
(yr) Sex
Smoking
History Histology
EGFR
Mutation
Daily Dose
Erlotinib (Line
of Therapy)
Response
(RECIST)
PFS
(mo) Rash Diarrhea Other
1 55 M Former
(60 py)
Adenocarcinoma delE746_A750 25 mg (first line) PR 6 None (0) None (0) None
2 64 F Never Adenocarcinoma delE746_A750 25 mg (first line) PR 8 None (0) None (0) None
3 65 F Former
(30 py)
Adenocarcinoma delL747_T751
 R776S
25 mg (first line)a PR 11 None (0) None (0) LFT (2)
4 46 M Former
(30 py)
NSCLC, poorly
differentiated
L858R 25 mg (second line) SD 4 Yes (1) None (0) None
5 67 F Current
(1.5 py)
Adenocarcinoma Exon 19
deletionb
25 mg (first line) PR 10 Yes (1) None (0) None
6 69 F Former
(0.5 py)
Adenocarcinoma Exon 19
deletionb
25 mg (second line) SD 17 None (0) None (0) None
7 86 F Former
(30 py)
Adenocarcinoma L858R 25 mg (first line)c PR 35 None (0) None (0) None
a Patient 3 had her dose of erlotinib reduced to 25 mg every other day after LFT abnormalities were noted. All other patients remained on erlotinib daily until disease progression.
Patients 1–4 were followed up at Beth Israel Deaconess Medical Center and patients 5–7 at Memorial Sloan-Kettering Cancer Center.
b Exon 19 deletions were detected using length analysis of fluorescently labeled PCR in patients 5 and 6, and no further characterization of the mutation by sequencing was
performed.
c Patient 6 had her dose of erlotinib increased to 50 mg/d after initial response to erlotinib 25 mg/d.
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PFS, progression-free survival; py, pack-years; CTCAE, common terminology criteria for adverse
events version 3.0; M, male; F, female; PR, partial response; SD, stable disease; , ongoing response; LFT, liver function test abnormalities.
FIGURE 2. Kaplan-Meier progression-free survival curve for
epidermal growth factor receptor–mutated patients treated
with erlotinib 25 mg/d.
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